RxDoctor Payments Data

Alexander Runowski, MD

Family Medicine · Battle Creek, MINPI 1154439339

Payments from drug & device makers

$8,580in general payments, 2019–2025

Across 275 payments — averaging $31.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$530
  • Boehringer Ingelheim$473
  • Teva Pharmaceuticals USA, Inc.$466
  • GSK$361
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$8,580100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,580 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$176,309
Medicare patients
402
Services billed
1,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban183$83,538
RexultiBrexpiprazole26$36,122
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$34,993
OzempicSemaglutide34$33,468
JardianceEmpagliflozin63$26,265
MyrbetriqMirabegron75$25,495
MounjaroTirzepatide15$16,033
RybelsusSemaglutide15$14,164
TrulicityDulaglutide14$13,999
Aimovig AutoinjectorErenumab-Aooe18$13,860
CreonLipase/Protease/Amylase16$13,726
XareltoRivaroxaban41$13,152
EntrestoSacubitril/Valsartan34$12,524
FarxigaDapagliflozin Propanediol21$10,466
Divalproex Sodium103$9,209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$320$83,538183 claims
Novo NordiskOzempic, Rybelsus$1,079$47,63249 claims
Otsuka America Pharmaceutical, Inc.Rexulti$279$36,12226 claims
GSKTrelegy Ellipta$361$34,99350 claims
Lilly USA, LLCMounjaro, Trulicity$530$30,03329 claims
Boehringer IngelheimJardiance, Pradaxa$473$28,63184 claims
Astellas Pharma US IncMyrbetriq$50$25,49575 claims
AstraZenecaFarxiga, Brilinta$1,960$17,02050 claims
AbbVieCreon$188$13,72616 claims
Johnson & JohnsonXarelto$90$13,15241 claims
NovartisEntresto$167$12,52434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Battle Creek

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →